Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(2R,3R,3aS,5aR,10R,10aR)-N-(3,4-dichlorophenyl)-10-hydroxy-4-oxo-2-phenyl-2,3,3a,4,5a,10-hexahydrofuro[2,3-c]indeno[1,2-b]furan-3-carboxamide | - |
Escherichia coli | |
(2R,3R,3aS,5aR,10S,10aR)-N-(3,4-dichlorophenyl)-10-hydroxy-4-oxo-2-phenyl-2,3,3a,4,5a,10-hexahydrofuro[2,3-c]indeno[1,2-b]furan-3-carboxamide | - |
Escherichia coli | |
(2Z)-2-(cyclopropylimino)-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | competitive with respect to Phe, selective for bacterial Phe-RS versus human Phe-RS, IC50: 0.002 mM | Enterococcus faecalis | |
(2Z)-2-(cyclopropylimino)-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | competitive with respect to Phe, selective for bacterial Phe-RS versus human Phe-RS, IC50: 0.00017 mM | Escherichia coli | |
(2Z)-2-(cyclopropylimino)-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | competitive with respect to Phe, selective for bacterial Phe-RS versus human Phe-RS, IC50: 0.0016 mM | Staphylococcus aureus | |
(2Z)-2-[(3-chlorophenyl)imino]-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | IC50: 600 nM | Enterococcus faecalis | |
(2Z)-2-[(3-chlorophenyl)imino]-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | IC50: 10 nM | Escherichia coli | |
(2Z)-2-[(3-chlorophenyl)imino]-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | IC50: 70 nM | Staphylococcus aureus | |
(3R,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | IC50: 5 nM | Enterococcus faecalis | |
(3R,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | IC50: 130 nM | Escherichia coli | |
(3R,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | IC50: 4 nM | Staphylococcus aureus | |
(3S,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | IC50: 820 nM | Enterococcus faecalis | |
(3S,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | IC50: 3200 nM | Escherichia coli | |
1-(3-[[4-(3,5-dichlorophenyl)piperazin-1-yl]sulfonyl]phenyl)-3-(1,3-thiazol-2-yl)urea | IC50: 15 nM | Escherichia coli | |
1-(3-[[4-(3,5-dichlorophenyl)piperazin-1-yl]sulfonyl]phenyl)-3-(1,3-thiazol-2-yl)urea | IC50: 15 nM | Haemophilus influenzae | |
1-(3-[[4-(3,5-dichlorophenyl)piperazin-1-yl]sulfonyl]phenyl)-3-(1,3-thiazol-2-yl)urea | IC50: 50 nM | Streptococcus pneumoniae | |
2-phenylacetamidine | competitive with respect to phenylalanine | Escherichia coli | |
benzylguanidine | competitive with respect to phenylalanine | Escherichia coli | |
L-phenylalanyl-adenylate | - |
Escherichia coli | |
N-benzyl-D-amphetamine | most potent competitive inhibitor, selectivity for bacterial enzyme | Escherichia coli | |
N-benzylbenzamidine | competitive with respect to phenylalanine | Escherichia coli | |
N-[2-(1H-indol-3-yl)ethyl]-3-[(1,3-thiazol-2-ylcarbamoyl)amino]benzenesulfonamide | IC50: 8 nM | Escherichia coli | |
N-[2-(1H-indol-3-yl)ethyl]-3-[(1,3-thiazol-2-ylcarbamoyl)amino]benzenesulfonamide | IC50: 8 nM | Haemophilus influenzae | |
N-[2-(1H-indol-3-yl)ethyl]-3-[(1,3-thiazol-2-ylcarbamoyl)amino]benzenesulfonamide | IC50: 50 nM | Staphylococcus aureus | |
ochratoxin A | - |
Escherichia coli |
KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|
0.05 | - |
L-Phe | - |
Staphylococcus aureus | |
0.05 | - |
L-Phe | - |
Haemophilus influenzae | |
0.05 | - |
L-Phe | - |
Escherichia coli | |
0.05 | - |
L-Phe | - |
Enterococcus faecalis | |
0.05 | - |
L-Phe | - |
Streptococcus pneumoniae |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Enterococcus faecalis | - |
- |
- |
Escherichia coli | - |
- |
- |
Haemophilus influenzae | - |
- |
- |
Staphylococcus aureus | - |
- |
- |
Streptococcus pneumoniae | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
ATP + L-Phe + tRNAPhe | - |
Enterococcus faecalis | AMP + diphosphate + L-phenylalanyl-tRNAPhe | - |
? | |
ATP + L-phenylalanine + tRNAPhe | - |
Staphylococcus aureus | AMP + diphosphate + L-phenylalanyl-tRNAPhe | - |
? | |
ATP + L-phenylalanine + tRNAPhe | - |
Haemophilus influenzae | AMP + diphosphate + L-phenylalanyl-tRNAPhe | - |
? | |
ATP + L-phenylalanine + tRNAPhe | - |
Streptococcus pneumoniae | AMP + diphosphate + L-phenylalanyl-tRNAPhe | - |
? |
Synonyms | Comment | Organism |
---|---|---|
Phe-RS | - |
Staphylococcus aureus |
Phe-RS | - |
Haemophilus influenzae |
Phe-RS | - |
Escherichia coli |
Phe-RS | - |
Enterococcus faecalis |
Phe-RS | - |
Streptococcus pneumoniae |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.00014 | - |
N-benzyl-D-amphetamine | - |
Escherichia coli | |
0.058 | - |
N-benzylbenzamidine | - |
Escherichia coli | |
0.077 | - |
benzylguanidine | - |
Escherichia coli | |
0.23 | - |
2-phenylacetamidine | - |
Escherichia coli |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.000004 | - |
IC50: 4 nM | Staphylococcus aureus | (3R,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | |
0.000005 | - |
IC50: 5 nM | Enterococcus faecalis | (3R,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | |
0.000008 | - |
IC50: 8 nM | Haemophilus influenzae | N-[2-(1H-indol-3-yl)ethyl]-3-[(1,3-thiazol-2-ylcarbamoyl)amino]benzenesulfonamide | |
0.000008 | - |
IC50: 8 nM | Escherichia coli | N-[2-(1H-indol-3-yl)ethyl]-3-[(1,3-thiazol-2-ylcarbamoyl)amino]benzenesulfonamide | |
0.00001 | - |
IC50: 10 nM | Escherichia coli | (2Z)-2-[(3-chlorophenyl)imino]-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | |
0.000015 | - |
IC50: 15 nM | Haemophilus influenzae | 1-(3-[[4-(3,5-dichlorophenyl)piperazin-1-yl]sulfonyl]phenyl)-3-(1,3-thiazol-2-yl)urea | |
0.000015 | - |
IC50: 15 nM | Escherichia coli | 1-(3-[[4-(3,5-dichlorophenyl)piperazin-1-yl]sulfonyl]phenyl)-3-(1,3-thiazol-2-yl)urea | |
0.00005 | - |
IC50: 50 nM | Staphylococcus aureus | N-[2-(1H-indol-3-yl)ethyl]-3-[(1,3-thiazol-2-ylcarbamoyl)amino]benzenesulfonamide | |
0.00005 | - |
IC50: 50 nM | Streptococcus pneumoniae | 1-(3-[[4-(3,5-dichlorophenyl)piperazin-1-yl]sulfonyl]phenyl)-3-(1,3-thiazol-2-yl)urea | |
0.00007 | - |
IC50: 70 nM | Staphylococcus aureus | (2Z)-2-[(3-chlorophenyl)imino]-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | |
0.00013 | - |
IC50: 130 nM | Escherichia coli | (3R,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | |
0.00017 | - |
competitive with respect to Phe, selective for bacterial Phe-RS versus human Phe-RS, IC50: 0.00017 mM | Escherichia coli | (2Z)-2-(cyclopropylimino)-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | |
0.0006 | - |
IC50: 600 nM | Enterococcus faecalis | (2Z)-2-[(3-chlorophenyl)imino]-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | |
0.00082 | - |
IC50: 820 nM | Enterococcus faecalis | (3S,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone | |
0.0016 | - |
competitive with respect to Phe, selective for bacterial Phe-RS versus human Phe-RS, IC50: 0.0016 mM | Staphylococcus aureus | (2Z)-2-(cyclopropylimino)-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | |
0.002 | - |
competitive with respect to Phe, selective for bacterial Phe-RS versus human Phe-RS, IC50: 0.002 mM | Enterococcus faecalis | (2Z)-2-(cyclopropylimino)-3-(2-thienylmethyl)-1,3-thiazolidin-4-one | |
0.0032 | - |
IC50: 3200 nM | Escherichia coli | (3S,3aR,6aS)-5-(3,4-dichlorophenyl)-3-phenyl-3a,6a-dihydrospiro[furo[3,4-c]pyrrole-1,2'-indene]-1',3',4,6(3H,5H)-tetrone |